Effects of Respiratory Muscle Training in Individuals With Long-term Post-COVID-19 Symptoms

Sponsor
Universidad Complutense de Madrid (Other)
Overall Status
Recruiting
CT.gov ID
NCT05597774
Collaborator
Colegio Profesional de Fisioterapeutas de la Comunidad de Madrid (Other)
64
1
2
13.7
4.7

Study Details

Study Description

Brief Summary

The main objective of the present study is to observe the short-term effects of respiratory muscle training combined with an exercise training program on quality of life and exercise tolerance in individuals with long-term post-COVID-19 symptoms. As secondary objectives, the effects on respiratory muscle function, physical and lung function, as well as on the psychological state of these individuals.

Condition or Disease Intervention/Treatment Phase
  • Other: Inspiratory + expiratory muscle training group
  • Other: Inspiratory + expiratory muscle training sham group
  • Other: Exercise training program
N/A

Detailed Description

It is a double-blind randomized clinical trial study. Each participant will be randomly assigned to one of the following groups: 1) Exercise training program + Inspiratory muscle training + Expiratory muscle training, 2) Exercise training program + Sham Inspiratory muscle training + Sham Expiratory muscle training.

The exercise training program will be delivered in hospital and will be applied 2 sessions per week during 8 weeks. The exercise component will be lasted for 1hour and it consisted of cardiovascular exercises.

The respiratory muscle training program will be applied twice a day, 3 sessions per week during 8 weeks by a threshold device. The evening sessions will be supervised by a physiotherapist through a virtual platform.

Participants received baseline assessments at the beginning of the intervention and post-intervention assessments at the end of the 8th week.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
64 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effects of Respiratory Muscle Training Combined With an Exercise Training Program in Individuals With Long-term Post-COVID-19 Symptoms
Actual Study Start Date :
Oct 28, 2022
Anticipated Primary Completion Date :
Dec 19, 2023
Anticipated Study Completion Date :
Dec 19, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exercise training + Inspiratory and expiratory muscle training group

Participants will perform a cardiovascular exercise program 2 days per week during 8 weeks in the hospital, combined with an inspiratory and expiratory muscle training by a threshold device at home, twice a day, 3 days per week, for 8 weeks supervised by a physiotherapist through a virtual platform.

Other: Inspiratory + expiratory muscle training group
Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.

Other: Exercise training program
Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.

Sham Comparator: Exercise training + Inspiratory and expiratory muscle training sham group

Participants will perform a cardiovascular exercise program 2 days per week during 8 weeks in the hospital, combined with an inspiratory and expiratory muscle training by a sham threshold device at home, twice a day, 3 days per week, for 8 weeks supervised by a physiotherapist through a virtual platform.

Other: Inspiratory + expiratory muscle training sham group
Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.

Other: Exercise training program
Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.

Outcome Measures

Primary Outcome Measures

  1. Change in quality of life [Baseline and 1-week post-intervention (9 weeks from baseline)]

    Change in quality of life between baseline and post-intervention, as measured by the EuroQol-5D questionnaire which consists of 5 dimensions with 5 response options based on severity level, ranging from 1 to 5. An index score is provided, ranging from 0 (death) to 1 (full health).

  2. Change in exercise tolerance [Baseline and 1-week post-intervention (9 weeks from baseline)]

    Change in exercise tolerance between baseline and post-intervention, as measured by a cardiopulmonary exercise test

Secondary Outcome Measures

  1. Change in respiratory muscle function [Baseline and 1-week post-intervention (9 weeks from baseline)]

    Change in inspiratory/expiratory muscle strength and inspiratory muscle endurance between baseline and post-intervention, as measured by maximum static inspiratory and expiratory pressures and by a constant load breathing test

  2. Change in physical function [Baseline and 1-week post-intervention (9 weeks from baseline)]

    Change in lower and upper limb strength between baseline and post-intervention, as measured by 1-min Sit-to-Stand and peripheral muscle force (dynamometry)

  3. Change in pulmonary function [Baseline and 1-week post-intervention (9 weeks from baseline)]

    Change in pulmonary function and diffusion capacity for carbon monoxide between baseline and post-intervention, as measured by pulmonary function tests

  4. Change in psychological status [Baseline and 1-week post-intervention (9 weeks from baseline)]

    Change in anxiety/depression levels between baseline and post-intervention, as measured by Hospital Anxiety and Depression Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Over 18 years who presented long-term post-COVID-19 symptoms of fatigue and dyspnoea for at least 3 months after the COVID-19 diagnosis
Exclusion Criteria:
  • Progressive respiratory, neuromuscular or neurological disorders and/or psychiatric or cognitive conditions that hindered their ability to cooperate

  • Comorbidity that could interfere with the study interventions

  • Any contraindication to the training interventions

  • Previous inclusion in a rehabilitation program for their long-term post-COVID-19 symptoms (previous 3 months)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Universitario 12 de Octubre de Madrid Madrid Spain 28041

Sponsors and Collaborators

  • Universidad Complutense de Madrid
  • Colegio Profesional de Fisioterapeutas de la Comunidad de Madrid

Investigators

  • Principal Investigator: Ibai López de Uralde, PhD, Universidad Complutense de Madrid

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Universidad Complutense de Madrid
ClinicalTrials.gov Identifier:
NCT05597774
Other Study ID Numbers:
  • 21/747
First Posted:
Oct 28, 2022
Last Update Posted:
Oct 31, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Universidad Complutense de Madrid
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 31, 2022